Videos

“It definitely makes it easier for providers [to counsel patients]," says Landon Trost, MD.

“When I talk to physicians outside of urology, as well as within urology, much of the hesitation with using Cost Plus Drugs is that it seems complicated to use, when in reality, the process is actually very simple," says Raymond Xu, MD.

“To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” says Ekene Enemchukwu, MD, MPH, FACS, URPS.

"A lot of people are using [single-use ureteroscopes] nowadays, and part of it is because it really enhances our ability to provide guaranteed care, because we don't have to rely on the reusability of scopes," says Perry Xu, MD.

"This study was an investigator initiated study, and what they wanted to do was a randomized trial for large prostates, so 80 to 180 grams, between Aquablation and prostate enucleation," says Naeem Bhojani, MD, FRCSC.

"This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD.

"We demonstrate that patients with metastatic disease stayed on therapy longer—a median of 9 months vs 7 months for the non-metastatic patients," says Rana R. McKay, MD, FASCO.

"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD.

"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).

Experts discuss how they communicate various treatment options for non–muscle-invasive bladder cancer (NMIBC) with patients and health care professionals.

"I think AI is going to have a significant role. We're just at the tip of the iceberg," says Jason M. Hafron, MD, CMO.

"They are risking their own lives for their job, so it's the part of the whole community to do our best to try to keep them safe," says Sima P. Porten, MD, MPH.

Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.

Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.

“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having decreased] morbidity from repeated resections, and saving bladders in the process," says Eugene B. Cone, MD.

"We recognize that an 11% increase in success may not seem that clinically significant, but I think every little bit helps," says Kate H. Kraft, MD, MHPE, FACS, FAAP.

“I always encourage urologists and physicians in general to keep up with the organizations that they're a part of, like the AUA, that often advocate on your behalf," says Ruchika Talwar, MD.

"I say with a lot of confidence, just continue using telehealth as you are," says Chad Ellimoottil, MD, MS.

A panelist discusses how benign prostatic hyperplasia (BPH) management involves a comprehensive patient journey that encompasses initial diagnostic evaluation, tailored pharmacological interventions including α-blockers and 5-α reductase inhibitors, and a progressive treatment approach ranging from conservative drug therapy to potential surgical options based on symptom severity and patient response.

"I'm all for this great effort by ImmunityBio to provide us with an alternative option,” says Suzanne B. Merrill, MD, FACS.

"Viral vectors are basically a blueprint of the virus that's used to carry the DNA payload into the target tissue, but the problem is they have some issues," says Katherine Chan, MD, MPH.

“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer," says Dr Louise Kostos.

"For other health care professionals aiming to advocate for equitable changes within their system, it's really important to just start conversations about what you're noticing," says Hailey Frye.

John A. Taylor, III, MD, MS, discussed the new wealth of options in non–muscle invasive bladder cancer, specifically highlighting detalimogene voraplasmid.

"In a practice like mine, where approximately 30% of the practice is low testosterone, it'll have actually very little negative effect," says John P. Mulhall, MD.

“What's really cool about overactive bladder is that, it's not like high blood pressure. They do not have to leave this office with a pill in hand," says Anna Myers, CNP.

"The objective of this project [was] to clinically adjudicate the complications identified by that outpatient software," says Timothy D. Lyon, MD.

“One important aspect to get across…is that access to this EAP is pretty easy," says Suzanne B. Merrill, MD, FACS.

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.